Physician profile
Amy Scanlon
NPI 1922426717
$15,772.48
in general payments reported to CMS, 2019-2025
43 companies · $2,959 in 2025
The $2,959 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,944 · 2022: $3,902 · 2023: $3,200 · 2024: $2,768 · 2025: $2,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,829 · Education: $97.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,828.98 |
| Education | $97.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $2,889.84 | 2021-2025 | Afrezza |
| Novo Nordisk INC | $1,525.46 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,176.01 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $891.08 | 2021-2025 | Unithroid |
| Abbott Laboratories | $743.63 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $694.32 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $651.47 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $606.96 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $599.36 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $597.44 | 2021-2025 | |
| Amgen INC. | $571.49 | 2021-2025 | Evenity, Repatha, Repatha |
| Cequr Corporation | $542.39 | 2021-2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $534.34 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.41 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Ascendis Pharma Endocrinology INC | $319.36 | 2025 | Yorvipath |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $290.15 | 2024-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals Lp | $261.25 | 2021-2023 | Farxiga |
| Antares Pharma, INC. | $246.83 | 2024-2025 | Xyosted |
| Tolmar, INC. | $229.58 | 2023-2025 | Jatenzo |
| Intuity Medical INC | $195.75 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ibsa Pharma INC. | $185.75 | 2021-2025 | Tirosint, Licart, Flector |
| Radius Health, INC. | $181.59 | 2021-2025 | |
| Dexcom, INC. | $162.69 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $147.87 | 2021-2025 | |
| Amarin Pharma, INC. | $140.15 | 2021-2022 | |
| Medtronic, INC. | $123.57 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Alexion Pharmaceuticals, INC. | $102.13 | 2021-2024 | Strensiq |
| Zealand Pharma US, INC. | $92.87 | 2021 | |
| Tandem Diabetes Care, INC. | $86.67 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $81.37 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.93 | 2021-2022 | |
| Pfizer INC. | $58.47 | 2023-2024 | |
| Halozyme INC | $49.57 | 2023 | |
| Madrigal Pharmaceuticals | $49.07 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $40.85 | 2022-2023 | Contrave |
| Clarus Therapeutics INC. | $40.02 | 2021 | |
| Verity Pharmaceuticals INC. | $35.97 | 2024-2025 | Tlando |
| Glaxosmithkline, LLC. | $16.16 | 2025 | Shingrix, Arexvy |
| Acella Pharmaceuticals, LLC | $15.73 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $15.00 | 2023 | Veozah |
| Rhythm Pharmaceuticals, INC. | $14.67 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.90 | 2023 | Adthyza |
| Beta Bionics, INC. | $12.36 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.